ADC Entered into an Exclusive License Agreement with Sobi to Develop and Commercialize Zynlonta (loncastuximab tesirine-lpyl) in EU and Select International Territories
Shots:
- ADC to receive $55M up front & is eligible to receive $50M upon regulatory approval of Zynlonta in 3L DLBCL by EC and ~$330M in additional regulatory & sales milestones along with royalties on net sales of Zynlonta in Sobi’s territories
- Sobi will split some of the costs of specific international Zynlonta clinical trials & has a strong worldwide commercial infrastructure along with expertise in haematology & rare diseases
- Zynlonta is expected to be available in Q1’23 after a regulatory decision. ADC & MTPC collaborated to develop & commercialize Zynlonta for all hematologic & solid tumors in Japan while ADCT is now conducting a registrational P-II trial of Zynlonta in r/r DLBCL in China under the collaboration with ADC
Ref: Bussinesswire | Image: ADC Therapeutics
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
